Buy Bristol-Myers Squibb

Logo for stock BMY (Bristol-Myers Squibb)

Amount

£
GBP

Latest price

$51.48
(£1.00 = $1.321)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$103.183B

P/E ratio

-11.49

EPS

-$4.414

Beta

0.44

Dividend rate

$2.42

Dividend yield

4.77%

About

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.

CEO

Dr. Christopher S. (Chris) Boerner, Ph.D.

Employees

34,100

Sector

Health

Company HQ

PRINCETON, United States of America

Website

News

Logo for news article #0 (Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It)

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Investors Business Daily

April 14, 2025

Logo for news article #1 (Bristol Myers' heart disease drug fails to meet main goals in late-stage study)

Bristol Myers' heart disease drug fails to meet main goals in late-stage study

Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.

Reuters

April 14, 2025

Logo for news article #2 (Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial)

Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial.

Business Wire

April 14, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.